Xin X Chen

US Patent:

7700594, Apr 20, 2010

Filed:

Nov 15, 2006

Appl. No.:

11/599663

Inventors:

Xin Chen - Farmingdale NY, US
Heather Coate - Farmingdale NY, US
Andrew Philip Crew - Farmingdale NY, US
Ayako Honda - Farmingdale NY, US
Mark Joseph Mulvihill - Farmingdale NY, US
Paula A. R. Tavares - Farmingdale NY, US
Jing Wang - Farmingdale NY, US
Douglas S. Werner - Farmingdale NY, US
Kristen Michelle Mulvihill - Farmingdale NY, US
Kam W. Siu - Farmingdale NY, US
Bijoy Panicker - Farmingdale NY, US
Apoorba Bharadwaj - Farmingdale NY, US
Lee D. Arnold - Farmingdale NY, US
Meizhong Jin - Farmingdale NY, US
Brian Volk - Farmingdale NY, US
Qinghua Weng - Farmingdale NY, US
James David Beard - Farmingdale NY, US

Assignee:

OSI Pharmaceuticals, Inc. - Melville NY

International Classification:

C07D 487/04
C07D 401/14
C07D 403/04
A61K 31/53
A61K 31/4523
A61K 35/00

US Classification:

514243, 544184

Abstract:

Compounds represented by Formula (I).

US Patent:

7714013, May 11, 2010

Filed:

Aug 28, 2006

Appl. No.:

11/511163

Inventors:

Adnan M. M. Mjalli - Oak Ridge NC, US
Robert C. Andrews - Jamestown NC, US
Ramesh Gopalaswamy - Jamestown NC, US
Anitha Hari - High Point NC, US
Kwasi A. Avor - High Point NC, US
Ghassan Qabaja - Jamestown NC, US
Xiao-Chuan Guo - High Point NC, US
Suparna Gupta - Greensboro NC, US
David R. Jones - Asheboro NC, US
Xin Chen - High Point NC, US

Assignee:

Transtech Pharma, Inc. - High Point NC

International Classification:

A61K 31/4164
A61K 31/4178
C07D 233/64
C07D 403/02

US Classification:

514397, 514399, 548110, 5483147, 5483361

Abstract:

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

US Patent:

7737285, Jun 15, 2010

Filed:

May 3, 2007

Appl. No.:

11/800085

Inventors:

Adnan M. M. Mjalli - Oak Ridge NC, US
Robert C. Andrews - Jamestown NC, US
Ramesh Gopalaswamy - Jamestown NC, US
Anitha Hari - High Point NC, US
Kwasi A. Avor - High Point NC, US
Ghassan Qabaja - Jamestown NC, US
Xiao-Chuan Guo - High Point NC, US
Suparna Gupta - Greensboro NC, US
David R. Jones - Asheboro NC, US
Xin Chen - High Point NC, US

Assignee:

TransTech Pharma, Inc. - High Point NC

International Classification:

C07D 233/61
A01N 43/50

US Classification:

5483401, 514400

Abstract:

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

US Patent:

8111957, Feb 7, 2012

Filed:

Jul 7, 2009

Appl. No.:

12/498591

Inventors:

Robert R Alfano - Bronx NY, US
Xin Chen - Corning NY, US
Joohyun Koh - Painted Post NY, US
Ming-Jun Li - Horseheads NY, US
Daniel Aloysius Nolan - Corning NY, US
Henry Sztul - New York NY, US

Assignee:

Corning Incorporated - Corning NY

International Classification:

G02B 6/26
G01N 21/00

US Classification:

385 28, 356 731

Abstract:

Generation of a cylindrically polarized light beam, and in particular, a hybrid-azimuthal-radial polarization beams, called HARP modes, generated from an input linearly polarized Gaussian beam using a spun optical waveguide device is taught. The HARP modes are comprised of hybrid-azimuthal polarization (HAP) and hybrid-radial polarization (HRP) superposition modes. These beams possess a non-zero local angular momentum density that is spatially varying and a zero total angular momentum.

US Patent:

7361678, Apr 22, 2008

Filed:

Mar 5, 2003

Appl. No.:

10/382203

Inventors:

Adnan M. M. Mjalli - Oak Ridge NC, US
Robert C. Andrews - Jamestown NC, US
Ramesh Gopalaswamy - Jamestown NC, US
Anitha Hari - High Point NC, US
Kwasi S. Avor - High Point NC, US
Ghassan Qabaja - Jamestown NC, US
Xiao-Chuan Guo - High Point NC, US
Suparna Gupta - Greensboro NC, US
David R. Jones - Asheboro NC, US
Xin Chen - High Point NC, US

Assignee:

TransTech Pharma, Inc. - High Point NC

International Classification:

A61K 31/4164
A61K 31/4178
C07D 233/64
C07D 403/02

US Classification:

514397, 514399, 548110, 5483147, 5483361

Abstract:

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

US Patent:

20060135609, Jun 22, 2006

Filed:

Oct 21, 2005

Appl. No.:

11/255478

Inventors:

Eric Toone - Durham NC, US
David Epstein - Bahama NC, US
Pratap Challa - Durham NC, US
Phillip Snyder - Cambridge MA, US
Xin Chen - Chapel Hill NC, US
Mitchell deLong - Raleigh NC, US

Assignee:

Duke University - Durham NC

International Classification:

A61K 31/225

US Classification:

514547000

Abstract:

The present invention relates generally to ophthamological drugs. More specifically, the inventon relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance with the instant method and to the use of same in treating conditions associated with elevated intraocular pressure, particularly, glaucoma.

US Patent:

20070208053, Sep 6, 2007

Filed:

Jan 18, 2007

Appl. No.:

11/654814

Inventors:

Lee Arnold - Farmingdale NY, US
Xin Chen - Farmingdale NY, US
Hanqing Dong - Farmingdale NY, US
Andrew Garton - Farmingdale NY, US
Mark Mulvihill - Farmingdale NY, US
Colin Sambrook Smith - Oxford, GB
Gerard Thomas - Oxford, GB
Thomas Krulle - Oxford, GB
Jing Wang - Farmingdale NY, US

International Classification:

C07D 471/02
A61K 31/4745

US Classification:

514300000, 546113000

Abstract:

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X, X, X, X, X, X, X, R, and Qare defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the treatment of inflammation, allergy, asthma, disease and conditions of the immune system, disease and conditions of the nervous system, cardiovascular diseases, disease and conditions of the eye, dermatological diseases, osteoporosis, diabetes, multiple sclerosis, and infections.

US Patent:

20090318542, Dec 24, 2009

Filed:

Jul 29, 2009

Appl. No.:

12/511861

Inventors:

Eric J. Toone - Durham NC, US
David L. Epstein - Bahama NC, US
Pratap Challa - Durham NC, US
Phillip W. Snyder - Cambridge MA, US
Xin Chen - Chapel Hill NC, US
Mitchell A. deLong - Raleigh NC, US

International Classification:

A61K 31/381
A61K 31/235

US Classification:

514443, 514448, 514545

Abstract:

The present invention relates generally to ophthamological drugs. More specifically, the invention relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance with the instant method and to the use of same in treating conditions associated with elevated intraocular pressure, particularly, glaucoma.